Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Mar;39(3):763–765. doi: 10.1128/AAC.39.3.763

In vitro effects of sulfadiazine and its metabolites alone and in combination with pyrimethamine on Toxoplasma gondii.

E Schoondermark-van de Ven 1, T Vree 1, W Melchers 1, W Camps 1, J Galama 1
PMCID: PMC162621  PMID: 7793889

Abstract

Sulfadiazine and the metabolites N4-acetyl-sulfadiazine, 4-OH-sulfadiazine, 5-OH-sulfadiazine, 5-OH-glucuronide-sulfadiazine, and 5-OH-sulfate-sulfadiazine were tested separately and in combination with pyrimethamine for the inhibitory activity on Toxoplasma gondii growth in vitro. Except for N4-acetyl-sulfadiazine, all sulfa compounds possessed anti-Toxoplasma activity. The addition of 0.05 micrograms of pyrimethamine per ml, a concentration which in itself is not inhibitory, potentiated the microbial activity of sulfadiazine and its metabolites 100 fold.

Full Text

The Full Text of this article is available as a PDF (174.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chang H. R., Jefford C. W., Pechère J. C. In vitro effects of three new 1,2,4-trioxanes (pentatroxane, thiahexatroxane, and hexatroxanone) on Toxoplasma gondii. Antimicrob Agents Chemother. 1989 Oct;33(10):1748–1752. doi: 10.1128/aac.33.10.1748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Derouin F., Chastang C. In vitro effects of folate inhibitors on Toxoplasma gondii. Antimicrob Agents Chemother. 1989 Oct;33(10):1753–1759. doi: 10.1128/aac.33.10.1753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Goodman N. W. Anaesthetic research: new approaches need fresh attitudes. Anaesthesia. 1990 Nov;45(11):985–987. doi: 10.1111/j.1365-2044.1990.tb14643.x. [DOI] [PubMed] [Google Scholar]
  4. Harris C., Salgo M. P., Tanowitz H. B., Wittner M. In vitro assessment of antimicrobial agents against Toxoplasma gondii. J Infect Dis. 1988 Jan;157(1):14–22. doi: 10.1093/infdis/157.1.14. [DOI] [PubMed] [Google Scholar]
  5. Howe D. K., Sibley L. D. Toxoplasma gondii: analysis of different laboratory stocks of the RH strain reveals genetic heterogeneity. Exp Parasitol. 1994 Mar;78(2):242–245. doi: 10.1006/expr.1994.1024. [DOI] [PubMed] [Google Scholar]
  6. Kovacs J. A., Allegra C. J., Swan J. C., Drake J. C., Parrillo J. E., Chabner B. A., Masur H. Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate. Antimicrob Agents Chemother. 1988 Apr;32(4):430–433. doi: 10.1128/aac.32.4.430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Mack D. G., McLeod R. New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. Antimicrob Agents Chemother. 1984 Jul;26(1):26–30. doi: 10.1128/aac.26.1.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Nain C. K., Sharma B., Mehta S. Disposition of sulphadiazine in rhesus monkeys. Indian J Exp Biol. 1982 Jan;20(1):70–73. [PubMed] [Google Scholar]
  9. Nouws J. F., Firth E. C., Vree T. B., Baakman M. Pharmacokinetics and renal clearance of sulfamethazine, sulfamerazine, and sulfadiazine and their N4-acetyl and hydroxy metabolites in horses. Am J Vet Res. 1987 Mar;48(3):392–402. [PubMed] [Google Scholar]
  10. Nouws J. F., Mevius D., Vree T. B., Baakman M., Degen M. Pharmacokinetics, metabolism, and renal clearance of sulfadiazine, sulfamerazine, and sulfamethazine and of their N4-acetyl and hydroxy metabolites in calves and cows. Am J Vet Res. 1988 Jul;49(7):1059–1065. [PubMed] [Google Scholar]
  11. Nouws J. F., Vree T. B., Hekster Y. A. In vitro antimicrobial activity of hydroxy and N4-acetyl sulphonamide metabolites. Vet Q. 1985 Jan;7(1):70–72. doi: 10.1080/01652176.1985.9693956. [DOI] [PubMed] [Google Scholar]
  12. Schoondermark-van de Ven E., Galama J., Vree T., Camps W., Baars I., Eskes T., Meuwissen J., Melchers W. Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine. Antimicrob Agents Chemother. 1995 Jan;39(1):137–144. doi: 10.1128/aac.39.1.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sheffield H. G., Melton M. L. Effect of pyrimethamine and sulfadiazine on the fine structure and multiplication of Toxoplasma gondii in cell cultures. J Parasitol. 1975 Aug;61(4):704–712. [PubMed] [Google Scholar]
  14. Vree T. B., Vree J. B., Beneken Kolmer E. W., Hekster Y. A. Novel oxidative pathways of sulphapyridine and sulphadiazine by the turtle Pseudemys scripta elegans. Vet Q. 1991 Oct;13(4):218–224. doi: 10.1080/01652176.1991.9694311. [DOI] [PubMed] [Google Scholar]
  15. Weiss L. M., Luft B. J., Tanowitz H. B., Wittner M. Pyrimethamine concentrations in serum during treatment of acute murine experimental toxoplasmosis. Am J Trop Med Hyg. 1992 Mar;46(3):288–291. doi: 10.4269/ajtmh.1992.46.288. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES